Literature DB >> 3384221

Abnormal regulation of pancreatic glucagon secretion in obese fa/fa rats.

F Rohner-Jeanrenaud1, B Jeanrenaud.   

Abstract

The results reported in the literature regarding glucagonaemia in genetically obese fa/fa rats are conflicting: normal, increased or decreased plasma glucagon levels have been reported. Due to the existence of several molecules endowed with glucagon-like immunoreactivity, it was thought that the conflicting data could be related to the degree of specificity of the different glucagon antibodies. Three antibodies that all qualified as being specific for pancreatic glucagon were used. It was found that, depending on the antibody, absolute values of basal glucagonaemia or arginine-induced glucagon output varied quantitatively and qualitatively in both lean and obese rats. When non-extracted basal or stimulated plasma samples were passed on a G-50 Sephadex column, glucagon-like immunoreactivity was present over a wide range of molecular weights, indicating the presence of non-pancreatic glucagon molecules. When an ethanol extraction was used, the fractions eluting from the G-50 Sephadex column contained only pancreatic glucagon immunoreactivity. It is concluded that ethanol extraction is necessary for the measurement of the 3500 daltons glucagon. Using this methodology it was found that: (1) basal glucagonaemia was low but identical in the two groups of rats; (2) arginine-induced glucagon secretion was greater in obese than in lean animals; (3) glucagonaemia was decreased by glucose administration in lean but not in obese rats. It is concluded that there are, in obese animals, dysfunctions of glucagon output that may play a role in their abnormal glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3384221     DOI: 10.1007/bf00290591

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  30 in total

1.  Separation of antibody-bound and unbound peptide hormones labelled with iodine-131 by talcum powder and precipitated silica.

Authors:  G Rosselin; R Assan; R S Yalow; S A Berson
Journal:  Nature       Date:  1966-10-22       Impact factor: 49.962

2.  Determination of pancreatic and gut glucagon-like immunoreactivity (GLI) in normal and diabetic subjects.

Authors:  L G Heding; S M Rasmussen
Journal:  Diabetologia       Date:  1972-12       Impact factor: 10.122

Review 3.  An hypothesis on the aetiology of obesity: dysfunction of the central nervous system as a primary cause.

Authors:  B Jeanrenaud
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

Review 4.  Neuro-endocrine disorders seen as triggers of the triad: obesity--insulin resistance--abnormal glucose tolerance.

Authors:  B Jeanrenaud; S Halimi; G van de Werve
Journal:  Diabetes Metab Rev       Date:  1985

5.  Portal levels of glucagon and insulin in VMH-lesioned rats.

Authors:  E Bobbioni; C Coscelli
Journal:  Horm Metab Res       Date:  1980-09       Impact factor: 2.936

6.  Correlation between morphology and function in isolated islets of the Zucker rat.

Authors:  A Hayek; W Woodside
Journal:  Diabetes       Date:  1979-06       Impact factor: 9.461

7.  Insulin and glucagon: plasma levels and pancreatic release in the genetically obese Zucker rat.

Authors:  G F Bryce; P R Johnson; A C Sullivan; J S Stern
Journal:  Horm Metab Res       Date:  1977-09       Impact factor: 2.936

8.  Insulin and obesity in the Zucker genetically obese rat "fatty".

Authors:  L M Zucker; H N Antoniades
Journal:  Endocrinology       Date:  1972-05       Impact factor: 4.736

9.  Involvement of the cholinergic system in insulin and glucagon oversecretion of genetic preobesity.

Authors:  F Rohner-Jeanrenaud; B Jeanrenaud
Journal:  Endocrinology       Date:  1985-02       Impact factor: 4.736

10.  Effect of ventromedial hypothalamic lesions on the secretion of somatostatin, insulin, and glucagon by the perfused rat pancreas.

Authors:  Y Goto; R G Carpenter; M Berelowitz; L A Frohman
Journal:  Metabolism       Date:  1980-10       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.